The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles

Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles

May 29, 2018 • By Marilynn Larkin

  • Tweet
  • Email
Print-Friendly Version / Save PDF

“I’ve used adalimumab for patients with both widespread moderate-to-severe psoriasis as well as for those with milder regional specific disease (scalp, palms/soles and nails),” she notes. “With guselkumab, on the other hand, I’ve not chosen to use it yet solely for these three areas, but rather to treat patients with widespread psoriasis, some of whom are affected in these specified areas.”

You Might Also Like
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe
  • Guselkumab Studied to Treat RA & Plaque Psoriasis

“There are some limitations to this study, though,” she adds. “Since this is a post-hoc study, it may not be generalizable to people affected only in these specific areas (i.e., with milder disease) as opposed to patients with widespread psoriasis that also happens to include these regional areas, which reflects the patients that were initially enrolled in Voyage 1 and 2.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Also, the cleanest data in this study is limited to 24 weeks,” she says, “so data on the nails, which take longer to get better, may not reflect the complete picture.”

The study was funded by Janssen, which manufactures guselkumab. Dr. Blauvelt and three coauthors have received fees from Janssen and five coauthors are employees of the company.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: A secondary analysis of two randomized clinical trials. JAMA Dermatol. 2018 May 16. doi: 10.1001/jamadermatol.2018.0793. [Epub ahead of print]

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, feet, guselkumab, hand, Psoriasis, scalp

You Might Also Like:
  • One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
  • International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe
  • Guselkumab Studied to Treat RA & Plaque Psoriasis
  • Guselkumab Studied to Treat RA, Plaque Psoriasis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.